Following the Q4 2022 report, Redeye returns with an updated assessment of Acarix. While the ending of 2022 was soft in terms of sales, the progress in the US and an anticipated sales ramp-up in the region in 2023 make for an exciting year ahead.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/